Yeji

$EDIT

Editas Medicine, Inc.

Runway:16 mo
NasdaqMarket cap: —CIK 0001650664

Upcoming catalysts

0 surfaced

No catalysts surfaced for EDIT yet.

Drug pipeline

Safety and efficacy assessments
Sickle Cell Disease
EDIT-301
Transfusion Dependent Beta Thalassemia
EDIT-101
Leber Congenital Amaurosis 10

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06363760Safety and efficacy assessments—Enrolling By Invitation2040-08-01
NCT05444894EDIT-301Phase 2Active Not Recruiting2025-09-01
NCT04853576EDIT-301Phase 2Active Not Recruiting2025-08-01
NCT03872479EDIT-101Phase 2Unknown2025-05-23
NCT03396042——Completed2022-05-06